Johnson & Johnson (JNJ) told Bloomberg that its job posting is not related to the expected decision on its licensing pact with Geron (GERN). “The job description outlines responsibilities for a variety of disease areas and potential products/line extensions that are consistent with what has been disclosed as part of the Janssen oncology hematology portfolio,” J&J told Bloomberg. Shares of Geron are off the day’s highs but remain up 25% to $5.06.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.